Dr Reddy’s Laboratories (UK) Limited v Boehringer Ingelheim International GmbH
Damages would not be an adequate remedy for either party due to market unpredictability, risk of further generic entry, and inability to quantify harm. Preservation of the status quo and DR's failure to clear the way for its generic launch justify granting the interim injunction sought by BI.
Source excerpt
- Patent validity
- Interim injunctions
- Spc protection
- Market exclusivity
- Generic entry
- Pharmaceutical pricing